BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 16280831)

  • 1. A novel computer based expert decision making model for prostate cancer disease management.
    Richman MB; Forman EH; Bayazit Y; Einstein DB; Resnick MI; Stovsky MD
    J Urol; 2005 Dec; 174(6):2310-8. PubMed ID: 16280831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based patient choice: a prostate cancer decision aid in plain language.
    Holmes-Rovner M; Stableford S; Fagerlin A; Wei JT; Dunn RL; Ohene-Frempong J; Kelly-Blake K; Rovner DR
    BMC Med Inform Decis Mak; 2005 Jun; 5():16. PubMed ID: 15963238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choose wisely: therapeutic decisions and quality of life in patients with prostate cancer.
    O'Rourke ME
    Clin J Oncol Nurs; 2007 Jun; 11(3):401-8. PubMed ID: 17623624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer.
    Davison BJ; Goldenberg SL; Wiens KP; Gleave ME
    Cancer Nurs; 2007; 30(5):E7-15. PubMed ID: 17876177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information and decision-making preferences of men with prostate cancer.
    Davison BJ; Degner LF; Morgan TR
    Oncol Nurs Forum; 1995 Oct; 22(9):1401-8. PubMed ID: 8539181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account?
    Chen RC; Clark JA; Manola J; Talcott JA
    Cancer; 2008 Jan; 112(1):61-8. PubMed ID: 18040996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer.
    Dahm P; Yeung LL; Chang SS; Cookson MS
    J Urol; 2008 Aug; 180(2):451-9; discussion 460. PubMed ID: 18550100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for prostate cancer: evaluating the evidence.
    Bhatnagar V; Kaplan RM
    Am Fam Physician; 2005 May; 71(10):1915-22. PubMed ID: 15926407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being.
    van Tol-Geerdink JJ; Leer JW; van Lin EN; Schimmel EC; Huizenga H; van Daal WA; Stalmeier PF
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):442-8. PubMed ID: 17765404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer.
    Davison BJ; So AI; Goldenberg SL
    BJU Int; 2007 Oct; 100(4):780-5. PubMed ID: 17578466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The patient's dilemma: prostate cancer treatment choices.
    Patel HR; Mirsadraee S; Emberton M
    J Urol; 2003 Mar; 169(3):828-33. PubMed ID: 12576794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating a decision aid for patients with localized prostate cancer in clinical practice.
    Isebaert S; Van Audenhove C; Haustermans K; Junius S; Joniau S; De Ridder K; Van Poppel H
    Urol Int; 2008; 81(4):383-8. PubMed ID: 19077396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early prostate cancer: hedonic prices model of provider-patient interactions and decisions.
    Jani AB; Hellman S
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1158-68. PubMed ID: 17881151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.
    Davison BJ; Oliffe JL; Pickles T; Mroz L
    Oncol Nurs Forum; 2009 Jan; 36(1):89-96. PubMed ID: 19136342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of video-based patient education for shared decision-making in the treatment of prostate cancer.
    Gomella LG; Albertsen PC; Benson MC; Forman JD; Soloway MS
    Semin Urol Oncol; 2000 Aug; 18(3):182-7. PubMed ID: 10975489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The participation experiences of localized prostate cancer patients in the treatment decision-making process].
    Chien CH; Chuang CK; Liu KL; Liu HE
    Hu Li Za Zhi; 2007 Feb; 54(1):35-42. PubMed ID: 17340546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference.
    Miller DC; Wei JT; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin PW; Sanda MG
    Urology; 2006 Jul; 68(1):166-71. PubMed ID: 16844457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of information on preference heterogeneity and individualized care.
    Basu A; Meltzer D
    Med Decis Making; 2007; 27(2):112-27. PubMed ID: 17409362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.